Drug Information Product Development
AI-Assisted Drug Information Product Development
GS Federal helps prevention, opioid-abatement, behavioral health, education, coalition, nonprofit, and public-sector partners develop source-backed drug information products using responsible AI-supported workflows, human review, source verification, and quality-control processes.
Human review
Prevention-focused language
Quality control
Update readiness
Source-Backed Product Workflow
- Request
- Sources
- Evidence Table
- Review
- Message Bank
- Products
Why This Matters
Prevention professionals and opioid-abatement partners often need timely, accurate, audience-specific materials on opioids, fentanyl, synthetic opioids, opioid-like substances, polysubstance use, and emerging drug trends. Drug information products are high-stakes public-facing materials. A fabricated statistic, outdated legal claim, unsupported safety statement, or misleading drug-effect description can damage trust and create risk.
AI can help accelerate research, drafting, summarization, and product planning, but only when paired with a structured process for source verification, uncertainty review, human review, and quality control.
What GS Federal Can Support Now
DIP-C is under development, but GS Federal can already support organizations using a structured, human-led version of the workflow. In this approach, AI may assist with organizing information, summarizing sources, drafting outlines, comparing language, and developing product concepts. GS Federal keeps the process grounded in source review, prevention expertise, claim checking, and human judgment.
Introducing DIP-C: Drug Information Product Creator
GS Federal is developing the Drug Information Product Creator, or DIP-C, as a structured workflow for turning drug-related questions and substance topics into source-traceable information product packages.
DIP-C is being designed around a simple principle: accurate prevention and drug education products should not begin with a final AI-generated document. They should begin with an approved evidence base.
The intended DIP-C workflow moves from intake and source discovery through evidence extraction, uncertainty review, drafting, fact-checking, revision, message-bank development, derivative product planning, product QA, and final package assembly. This structure is designed to help ensure that claims, citations, caveats, review status, and release readiness remain visible throughout the production process.
DIP-C is currently under development. In the meantime, GS Federal can support organizations using a more manual, human-led version of the same process.
The DIP-C Logic
Build the evidence base
Clarify the topic, audience, deliverables, tone, scope, defaults, and release assumptions; discover federal, public health, scientific, surveillance, regulatory, and contextual sources; extract claims, citations, source strength, confidence, caveats, product use, and approved language; and document weak evidence, disputed points, changing legal or regulatory status, and messaging cautions.
Draft and review the core product
Draft the information paper using evidence-table claims, verify claims and citations, revise when required, improve clarity and stigma-free language, and create an approved message bank for derivative products.
Create derivative products
Create product content plans from the approved message bank, draft designed or layout-ready products, run factual, editorial, visual, accessibility, citation, learning-design, and production checks, and assemble the final package.
Review before advancement
At every review gate, blocking and required issues return to the appropriate prior step for revision. The same review gate runs again, and advancement is allowed only when zero blocking and zero required issues remain.
Products This Process Can Support
Quality-Control Safeguards
The process is designed to prevent unsupported claims from moving into public-facing products. Blocking and required issues must return for revision and review before a product advances. Products remain drafts unless a designated human review process approves dissemination.
Source hierarchy
Federal, public health, and peer-reviewed sources carry more weight than marketplace or media sources.
Date-stamped changing claims
Legal, regulatory, surveillance, and rapidly changing claims should be date-stamped and updated when needed.
Prevention-focused language
Products should use non-stigmatizing language designed for prevention, education, and community-facing work.
Evidence before derivatives
Derivative products should not be created until the evidence table and approved message bank exist.
Product QA
Visual, accessibility, citation, learning-design, and production QA support attention, comprehension, retention, and file integrity.
Final package readiness
Final packages should include source inventory, evidence table, information paper, message bank, review reports, uncertainty memo, requested products, QA reports, release status, review date, and recommended update date.
Review Gates and Escalation
Blocking
Could make the product inaccurate, unsafe, misleading, legally risky, stigmatizing, inaccessible, unusable, or technically invalid. Must be fixed before advancement.
Required
Meaningfully affects quality, clarity, traceability, audience fit, accessibility, template compliance, or release readiness. Must be fixed before advancement.
Recommended
Would improve the product but is not necessary for safe, accurate, audience-ready use.
Optional
Stylistic preference, minor polish, or nice-to-have improvement.
Future update
Important but outside current scope or dependent on new evidence or later decisions.
Escalation
If blocking or required issues remain after two automated revision cycles, the issue should escalate to human review or a safer production method.
Why GS Federal
GS Federal’s drug information product development approach is grounded in prevention, opioid-abatement, drug education, training, technical assistance, curriculum development, and public-sector communication experience. Greg Pliler has worked in substance misuse prevention, drug education, opioid-related training, drug demand reduction, technical assistance, and prevention workforce development for more than two decades. This background shapes GS Federal’s focus on source-backed products, prevention-focused language, audience fit, human review, and practical implementation.
Prevention and opioid-abatement expertise
GS Federal understands high-stakes drug education and opioid-abatement communication environments.
Training and technical assistance experience
The process supports products that can be used in training, TA, office hours, and workforce development.
Source-backed product development
Workflows keep claims, sources, caveats, review status, and release readiness visible.
Public-sector and coalition communication
Materials are designed for practical use by agencies, coalitions, nonprofits, educators, and community-facing partners.
Related Services and Resources
AI for Prevention Services
AI for Substance Misuse Prevention and Opioid Abatement
AI Training for Opioid Abatement and Prevention Professionals
AI-Supported Emerging Drug Trend Monitoring
Responsible AI Use for the Prevention Workforce
PreventionCoach.ai
Need Source-Backed Drug Information Products?
GS Federal can help your team develop drug information papers, plain-language explainers, message banks, training materials, and prevention communication products using a responsible AI-supported process grounded in source verification, human review, and quality control.